We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Medicines Company | NASDAQ:MDCO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 84.90 | 84.00 | 84.94 | 0 | 01:00:00 |
The Medicines Company
|
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
|
000-31191
|
|
04-3324394
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
8 Sylvan Way
Parsippany, New Jersey
|
|
07054
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
(Former Name or Former Address, if Changed Since Last Report)
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
1.
|
The Company's stockholders voted to elect the following individuals as Class 1 directors of the Company, each for a one-year term expiring in 2018, or until their successors have been duly elected and qualified:
|
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
William W. Crouse
|
60,558,410
|
1,388,189
|
98,215
|
3,496,077
|
Fredric N. Eshelman
|
61,779,886
|
253,770
|
11,158
|
3,496,077
|
Robert J. Hugin
|
57,015,507
|
4,929,207
|
100,100
|
3,496,077
|
John C. Kelly
|
61,762,834
|
184,535
|
97,445
|
3,496,077
|
Clive A. Meanwell
|
61,736,453
|
296,602
|
11,759
|
3,496,077
|
Paris Panayiotopoulos
|
61,959,113
|
77,562
|
8,139
|
3,496,077
|
Hiroaki Shigeta
|
61,654,581
|
289,324
|
100,909
|
3,496,077
|
Elizabeth H.S. Wyatt
|
61,656,566
|
288,290
|
99,958
|
3,496,077
|
2.
|
The Company's executive compensation was approved, on an advisory basis, based upon the following votes:
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
61,405,916
|
528,630
|
110,268
|
3,496,077
|
3.
|
The Company's stockholders voted, on an advisory basis, for the Company to hold advisory votes on executive compensation on an annual basis, based upon the following votes:
|
1 Year
|
2 Years
|
3 Years
|
Abstain
|
Broker Non-Votes
|
57,090,651
|
17,471
|
4,834,835
|
101,857
|
3,496,077
|
4.
|
The independent registered public accounting firm for the current fiscal year was ratified based upon the following votes:
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
65,345,285
|
191,747
|
3,859
|
—
|
|
THE MEDICINES COMPANY
|
||||
|
|||||
|
|||||
Date: May 31, 2017
|
By:
|
/s/ Stephen M. Rodin
|
|||
|
Stephen M. Rodin
|
||||
|
|
|
|
Executive Vice President and General Counsel
|
1 Year Medicines Chart |
1 Month Medicines Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions